Sage Journals: Discover world-class research

Abstract

Keywords

Drug-coated balloon drug-eluting balloon drug-eluting stent mortality paclitaxel

Get full access to this article

View all access options for this article.

References

Tepe

Laird

Schneider

et al ; IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502.

Rosenfield

Jaff

White

et al ; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.

Schroeder

Werner

Meyer

et al ; ILLUMENATE EU RCT Investigators. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon). Circulation. 2017;135(23):2227–2236.

Krishnan

Faries

Niazi

et al . Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136(12):1102–1113.

Micari

Brodmann

Keirse

et al ; IN.PACT Global Study Investigators. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT Global Study. JACC Cardiovasc Interv. 2018;11(10):945–953.

Ansel

Brodmann

Keirse

et al ; IN.PACT Global Study Investigators. Drug-coated balloon treatment of femoropopliteal lesions typically excluded from clinical trials: 12-month findings from the IN.PACT Global Study. J Endovasc Ther. 2018;25(6):673–682.

Iida

Soga

Urasawa

et al ; MDT-2113 SFA Japan Investigators. Drug-coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal arteries: one-year results of the MDT-2113 SFA Japan randomized trial. J Endovasc Ther. 2018;25(1):109–117.

Bausback

Willfort-Ehringer

Sievert

et al ; RANGER SFA Investigators. Six-month results from the initial randomized study of the Ranger paclitaxel-coated balloon in the femoropopliteal segment. J Endovasc Ther. 2017;24(4):459–467.

Thieme

Von Bilderling

Paetzel

et al ; Lutonix Global SFA Registry Investigators. The 24-month results of the Lutonix Global SFA Registry: worldwide experience with Lutonix drug-coated balloon. JACC Cardiovasc Interv. 2017;10(16):1682–1690.

10.

Vermassen

. SAVER: rationale and merits for an all-comers DCB e-Registry. Oral presentation at: LINC 2017; January 24, 2017; Leipzig, Germany. https://linc2017.cncptdlx.com/media/1355_Frank_Vermassen_24_01_2017_Room_6_-_Speakers_corner.pdf. Accessed December 20, 2018.

11.

Feldman

Armstrong

Aronow

et al . SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv. 2018 Apr 24. doi: 10.1002/ccd.27635.

12.

Cortese

Granada

Scheller

et al . Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J. 2016;37(14):1096–1103.

13.

Katsanos

. Paclitaxel-coated balloons in the femoropopliteal artery: it is all about the pharmacokinetic profile and vessel tissue bioavailability. JACC Cardiovasc Interv. 2016;9(16):1743–1745.

14.

Brodmann

. Is there a clinical class effect of drug-coated balloons in peripheral arteries? Oral presentation at LINC 2016; January 24, 2016; Leipsiz, Germany. https://linc2016.cncptdlx.com/media/1059_Marianne_Brodmann_27_01_2016_Room_5___Global_Expert_Exchange.pdf. Accessed December 20, 2018

15.

Giacoppo

Cassese

Harada

et al . Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016;9(16):1731–1742.

16.

Katsanos

Spiliopoulos

Paraskevopoulos

et al . Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23(2):356–370.

17.

Cremers

Biedermann

Mahnkopf

et al . Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol. 2009;98(5):325–330.

18.

Gongora

Shibuya

Wessler

et al . Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. JACC Cardiovasc Interv. 2015;8(8):1115–1123.

19.

Peterson

Hasenbank

Silvestro

et al . IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease. Adv Drug Deliv Rev. 2017;112:69–77.

20.

Schorn

Malinoff

Anderson

et al . The Lutonix® drug-coated balloon: A novel drug delivery technology for the treatment of vascular disease. Adv Drug Deliv Rev. 2017;112:78–87.

21.

Fusaro

Cassese

Ndrepepa

et al . Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. Int J Cardiol. 2013;168(4):4002–4009.

22.

Katsanos

Spiliopoulos

Karunanithy

et al . Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg. 2014;59(4):1123–1133.

23.

Cassese

Ndrepepa

Kufner

et al . Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis. EuroIntervention. 2017;13(4):483–489.

24.

Katsanos

Spiliopoulos

Kitrou

et al . Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245. DOI: 10.1161/JAHA.118.011245.

25.

Laird

Schneider

Tepe

et al . Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66(21):2329–2338.

26.

Dake

Ansel

Jaff

et al . Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472–1483.

27.

Smith

Ebrahim

. Data dredging, bias, or confounding. BMJ. 2002;325(7378):1437–1438.

Use of Paclitaxel-Eluting Technologies in the Femoropopliteal Segment Under Scrutiny Over Possible Link to Late All-Cause Mortality: Time to Panic or an Opportunity to Resurge?

Abstract

Keywords

Get full access to this article

References